A Phase 2 trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab + zimberelimab, and domvanalimab + zimberelimab + etrumadenant in front-line non-small cell lung cancer.
Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. Clinical studies with zimberelimab have demonstrated efficacy and safety that is consistent with currently approved anti-PD-1 therapies.
The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.
Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options.
Non-small cell lung cancer, PD-L1 positive (ARC-7)
Non-small cell lung cancer, EGFRmut (ARC-4)
Castration-resistant prostate cancer (ARC-6)
Castration-resistant prostate cancer (ARC-5)
Pancreatic adenocarcinoma (ARC-8)
Multiple Cancer Types (domvanalimab + Zimberelimab)
Multiple Cancer Types (Zimberelimab)